Christopher Y. Thomas, M.D.
Associate Professor, Hematology & Oncology
Academic: 434-243-6356 | Department: 336-716-4464
Dillon PM, Moskaluk C, Fracasso PM, Petroni GR, Thomas CY. Phase II study of dovitinib (TK1258) in patients with progressive metastatic adenoid cystic carcinoma [abstract]. J Clin Oncol. 2013;31(15 Suppl):6021.
Glisson BS, Tseng J, Marur S, Shin DM, Murphy BA, Cohen EEW, Thomas CY, Willey R, Cosaert J, William WN, Harun N, Lee JJ, Haddad RI. Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN) [abstract]. J Clin Oncol. 2013;31(15 Suppl):6030.
Liu W, Xie CC, Thomas CY, Kim ST, Lindberg J, Egevad L, Wang Z, Zhang Z, Sun J, Sun J, Koty PP, Kader AK, Cramer SD, Bova GS, Zheng SL, Gronberg H, Isaacs WB, Xu J. Genetic markers associated with early cancer-specific mortality following prostatectomy
. Cancer. 2013;119(13):2405-2412.
Rahimi AS, Wilson DD, Saylor DK, Stelow EB, Thomas CY, Reibel JF, Levine PA, Shonka DC, Jameson MJ, Read PW. p16, Cyclin D1, and HIF-1alpha predict outcomes of patients with oropharyngeal squamous cell carcinoma treated with definitive intensity-modulated radiation therapy
. Int J Otolaryngol. 2012;2012():685951.
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.